MDWD · MediWound Ltd.
AI read · Good for MDWD
The AI's read
MediWound reported Q2 revenue down to $3.1M from $5.7M, driven by BARDA timing, but flagged EscharEx Phase 3 progress and a $1.05B U.S. peak-sales estimate. Management also noted stronger NexoBrid U.S. commercialization, a Vericel MSA, and reaffirmed $24–26M full-year guidance. Market reaction is muted, stock up ~1.0% after the call and RSI 44, so nothing looks overstretched. The news looks new and actionable rather than already baked in, but the revenue miss tempers euphoria. We lean bullish. Clinical progress plus government-funded revenue and the Vericel agreement create asymmetric upside versus current valuation, while Phase 3 and commercialization risk keep this from being a slam dunk.